WillItSurvive
Medical technology and health companies · United States

agilon health

agilonhealth.com ↗

Runs value-based Medicare primary care in partnership with independent physician groups.

Losing its protection
Assessed 22 July 2026 · Evidence as of 22 July 2026
The structural protection is eroding.
On the recordSince 22 July 2026 · Checkable from August 2026 · Every call on the record Checkpoint: Q2 2026 earnings report, first full quarter under new CEO Tim O'Rourke
The call

agilon is stabilizing after a near-collapse year, but its profits still depend on a CMS payment formula it does not control and rivals that own more of the healthcare dollar.

Agilon Health signs up independent doctors to treat Medicare patients, taking on the financial risk if those patients get expensive care. For 20 years it built relationships with doctors and learned how to run this business profitably. The problem is that bigger companies like CVS, Humana, and UnitedHealth own their own doctors, pharmacies, and insurance plans all together, which lets them make more money and operate more efficiently than Agilon can. The real threat is not these competitors but the government itself: the Medicare agency changed how it pays for this type of care in 2025, which crushed Agilon's profits so badly the stock fell more than half. The company is trying to come back with a new CEO and smaller size, but whether it can stay profitable depends entirely on whether the government keeps paying enough or changes the rules again.

Why
01
AI pressure: None apparent. AI is not the pressure here, the risk is capitation math and regulator-set payment rates, not a software rival. Could AI do the core job? Unlikely.
02
Bigger players: CVS Health (Oak Street Health), Humana/CenterWell, UnitedHealth/Optum. These rivals own the insurer, pharmacy, and clinics together, so they keep more of every Medicare dollar than agilon can. Could a giant copy it? Yes, easily.
03
What protects it. Long, exclusive physician contracts and a non-insurer position that independent practices trust more than payor-owned buyers.
What would change this call
Q2/Q3 2026 earnings show adjusted EBITDA at or above the ~$25M FY2026 guidance midpoint. Would show the turnaround is holding rather than relapsing into losses.
Platform member count stabilizes or grows instead of continuing its 625K to 536K slide. Would show membership shrinkage was a one-time reset, not ongoing attrition to rivals.
Securities fraud class action settles without a major cash payout, or a physician group defects to CVS/Humana/Optum at contract renewal. Settlement size tests financial strain; a defection would show the physician-partner moat cracking.
Key numbers
  • FY2025 adjusted EBITDA: -$296 million (2026-02-25)
  • Q1 2026 adjusted EBITDA: +$54 million (2026-05-06)
  • Members fell from 625,000 to 536,000 (2026-05-06)
Named risks
  • CMS risk-adjustment methodology (V28) changes compress capitation margins sector-wide. Severity: high
  • Active securities fraud class action, lead-plaintiff deadline March 2, 2026, unresolved liability. Severity: medium
  • Vertically integrated giants CVS and Humana have structural payor-pharmacy-provider economics agilon lacks. Severity: high
  • Membership shrank from 625,000 to 536,000 in one quarter, reducing scale for capitation model. Severity: medium
  • New CEO started May 2026 mid-restructuring, execution risk during leadership handoff. Severity: medium
Rivals, as read in July 2026
RivalDirectionEvidence
CVS Health (Oak Street Health)gaining onOwns payor, pharmacy and provider assets; runs >230 Oak Street centers as of 2026-03-20 analysis
Humana/CenterWellgaining onVertically integrated payor-provider model competes for same independent physician groups
Privia Health, AledadecontestingTech-native peer enablers competing for the same independent primary care physician partnerships
P3 Health PartnerscontestingRegional MA capitation and delegated-risk peer model, per 2026-03-19 competitive analysis
Questions people ask
Is agilon health profitable in 2026?
Not meaningfully. After a -$296 million adjusted EBITDA loss on $5.933 billion revenue in FY2025 (reported 2026-02-25), agilon posted +$54 million adjusted EBITDA in Q1 2026 and guides to only ~$25 million adjusted EBITDA on ~$5.7 billion revenue for full-year 2026, under 0.5% margin.
Did agilon health's stock crash?
Yes. agilon suspended FY2025 guidance in August 2025, triggering a single-day stock drop of over 50% and a federal securities fraud class action covering February 26 to August 4, 2025, with a lead-plaintiff deadline of March 2, 2026.
Who owns agilon health?
agilon health has traded on NYSE as AGL since its April 15, 2021 IPO, which raised roughly $1.07 to $1.23 billion. Private equity firm Clayton, Dubilier & Rice, which formed the company in 2016, retained about 58% ownership immediately post-IPO.
Could AI replace agilon health?
Unlikely to replace its core business. agilon's moat is 20-year exclusive physician-partnership contracts, payor relationships, and Medicare risk-bearing regulatory infrastructure, not proprietary software. AI mainly touches risk-adjustment analytics at the margins, per company disclosures as of 2026-05-07.
Is agilon health laying off employees?
Headcount has shrunk materially: stockanalysis.com reports 856 employees as of December 31, 2025, down 220 (-20.45%) year over year, tied to a disclosed $30-35 million operating-cost reduction program announced 2026-02-25 alongside market exits.
Who is agilon health's biggest competitor?
CVS Health via Oak Street Health (over 230 centers) and Humana via CenterWell are the most structurally advantaged rivals, since both own payor, pharmacy, and provider assets in the same value-based senior care model that agilon must split economics away in its contracts.
Timeline
  • 2026-05-07Tim O'Rourke, ex-Humana, becomes CEO mid-restructuring
  • 2026-05-06Q1 2026 results: adjusted EBITDA +$54M, revenue $1.42B
  • 2026-03-02Securities fraud class action lead-plaintiff deadline
  • 2026-02-25FY2025 results: -$296M adj EBITDA on $5.933B revenue
  • 2026-01-01Disclosed market and payor exits finalized
  • 2025-08-01FY2025 guidance suspended, stock drops over 50% in a day
  • 2021-04-15IPO on NYSE as AGL, CD&R retains ~58% ownership
  • 2017-04Incorporated in Delaware as Agilon Health Topco, Inc.
  • 2016-10CD&R forms agilon health via acquisitions
Revision history
22 July 2026
First assessed. Losing its protection. The text above is fixed as of this date and is not edited afterwards.
In the same band
NeuralinkKingmed DiagnosticsMeinian Onehealth
More in Medical technology and health companies →
Sources